Pharmacokinetic differences corroborate observed low tacrolimus dosage in native American renal transplant patients

Drug Metabolism and Disposition

Volumn 39, Issue 11, 2011, Pages 2017-2019

  Grover, Anita ^a   Frassetto, Lynda A ^b   Benet, Leslie Z ^a   Chakkera, Harini A ^c  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; AMERICAN INDIAN; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; ETHNIC DIFFERENCE; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MORNING DOSAGE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

BAYES THEOREM; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIANS, NORTH AMERICAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 80054723852     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041350     Document Type: Article

References (11)

1. Bazin C, Guinedor A, Barau C, Gozalo C, Grimbert P, Duvoux C, Furlan V, Massias L, and Hulin A (2010) Evaluation of the Architect tacrolimus assay in kidney, liver, and heart transplant recipients. J Pharm Biomed Anal 53:997-1002.
2. Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, et al. (2009) Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 48:805-816.
3. Fitzsimmons WE, Bekersky I, Dressler D, Raye K, Hodosh E, and Mekki Q (1998) Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 30:1359-1364. (Pubitemid 28309604)
4. Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, and Christians U (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69:24-31. (Pubitemid 32108668)
5. Masuda S and Inui K (2006) An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112:184-198. (Pubitemid 44301492)
6. Neylan JF (1998) Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 65:515-523.
7. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, and de Fijter JW (2005) AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67:2440-2447. (Pubitemid 41623408)
8. Staatz CE, Willis C, Taylor PJ, and Tett SE (2002) Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 72:660-669. (Pubitemid 36021005)
9. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, and Habuchi T (2005) Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37:1730-1732. (Pubitemid 40790812)
10. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, and Kato T (2004) Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78:1182-1187. (Pubitemid 39426437)
11. Zhang Y and Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168. (Pubitemid 32324448)